PCI Expands Cryogenic Storage Facilities to Rockford Site

November 25, 2016
Pharmaceutical Technology Editors
PTSM: Pharmaceutical Technology Sourcing and Management
Volume 11, Issue 12

PCI is extending its cryogenic storage capabilities to its Rockford, Illinois operations to support storage and distribution of clinical trial materials.

PCI Pharma Services (PCI) announced that it is extending its cryogenic storage capabilities to its Rockford, Illinois operations. Clients will be able to store their temperature-sensitive products at the facility. This capability is also currently offered at PCI’s Bridgend, UK center for clinical trial services.

The Rockford development and the recent expansion in Bridgend reflect PCI investments in supporting specialized services for clinical trials. The new specialization is situated in the 93,000 square feet Logistics Parkway building at the PCI Rockford campus, a purpose-built facility supporting clinical trials storage and distribution. The site is one of seven facilities at the Rockford center of excellence.

The cold chain, ultra-cold chain, and cryogenic capabilities have enabled PCI to provide temperature-managed solutions that help reduce potential logistical and technical challenges with packaging, labelling, storage, and distribution of drug products at cryogenic temperatures. PCI has a specialized network capability for supporting temperature-sensitive drug product including ultra-cold chain, at temperatures ranging from controlled ambient 15–25°C, 2–8°C, down to -20°C, -30°C, -40°C, -60°C, and -90°C, including liquid nitrogen vapor phase storage at -196°C for advanced therapeutic medicinal products (ATMPs).  

Source: PCI